Details for New Drug Application (NDA): 022114

✉ Email this page to a colleague

NDA 022114 describes ZINGO, which is a drug marketed by Powder Pharms and is included in one NDA. It is available from one supplier. There are three patents protecting this drug. Additional details are available on the ZINGO profile page.

The generic ingredient in ZINGO is lidocaine hydrochloride. There are twenty-nine drug master file entries for this compound. Fifty-three suppliers are listed for this compound. Additional details are available on the lidocaine hydrochloride profile page.

Summary for 022114

Tradename:	ZINGO
Applicant:	Powder Pharms
Ingredient:	lidocaine hydrochloride
Patents:	3

Pharmacology for NDA: 022114

Physiological Effect	Local Anesthesia

Suppliers and Packaging for NDA: 022114

Tradename	Generic Name	Dosage	NDA	Application Type	Supplier	National Drug Code	Package Code	Package
ZINGO	lidocaine hydrochloride	SYSTEM;INTRADERMAL	022114	NDA	Powder Pharmaceutical Incorporated	61388-123	61388-123-26	12 POWDER in 1 POUCH (61388-123-26)
ZINGO	lidocaine hydrochloride	SYSTEM;INTRADERMAL	022114	NDA	Powder Pharmaceutical Incorporated	61388-123	61388-123-48	48 CARTON in 1 BOX (61388-123-48) / 12 POWDER in 1 CARTON (61388-123-12)

Profile for product number 001

Active Rx/OTC/Discontinued:	RX	Dosage:	SYSTEM;INTRADERMAL			Strength	0.5MG
Approval Date:	Aug 16, 2007	TE:		RLD:	No
Patent:	8,540,665	Patent Expiration:	Oct 22, 2029	Product Flag?		Substance Flag?		Delist Request?
Patented Use:	ZINGO INTRADERMAL INJECTION SYSTEM IS A DRUG DELIVERY SYSTEM THAT IS CAPABLE OF DELIVERING FINE DRY POWDERED LIDOCAINE HYDROCHLORIDE MONOHYDRATE FOR LOCAL ANESTHETIC ACTION
Patent:	9,358,338	Patent Expiration:	Apr 27, 2035	Product Flag?		Substance Flag?		Delist Request?
Patented Use:	ZINGO IS A POWDER INTRADERMAL SYSTEM THAT IS CAPABLE OF DELIVERING FINE DRY POWDERED LIDOCAINE HYDROCHLORIDE MONOHYDRATE FOR LOCAL ANESTHETIC ACTION
Patent:	9,370,622	Patent Expiration:	Sep 28, 2035	Product Flag?		Substance Flag?		Delist Request?
Patented Use:	ZINGO IS A POWDER INTRADERMAL SYSTEM THAT IS CAPABLE OF DELIVERING FINE DRY POWDERED LIDOCAINE HYDROCHLORIDE MONOHYDRATE FOR LOCAL ANESTHETIC ACTION

Expired US Patents for NDA 022114

Subscribe to access the full database, or Subscribe
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Powder Pharms	ZINGO	lidocaine hydrochloride	SYSTEM;INTRADERMAL	022114-001	Aug 16, 2007	5,630,796	⤷ Subscribe
Powder Pharms	ZINGO	lidocaine hydrochloride	SYSTEM;INTRADERMAL	022114-001	Aug 16, 2007	6,881,200	⤷ Subscribe
Powder Pharms	ZINGO	lidocaine hydrochloride	SYSTEM;INTRADERMAL	022114-001	Aug 16, 2007	6,004,286	⤷ Subscribe
Powder Pharms	ZINGO	lidocaine hydrochloride	SYSTEM;INTRADERMAL	022114-001	Aug 16, 2007	5,899,880	⤷ Subscribe
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.